```
=> s probucol/cn
L1            1 PROBUCOL/CN

=> d

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   23288-49-5  REGISTRY
ED   Entered STN:  16 Nov 1984
CN   Phenol, 4,4'-[(1-methylethylidene)bis(thio)]bis[2,6-bis(1,1-dimethylethyl)-
      (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Acetone, bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole (8CI)
CN   Phenol, 4,4'-(isopropylidenedithio)bis[2,6-di-tert-butyl- (8CI)
OTHER NAMES:
CN   4,4'-(Isopropylidenedithio)bis[2,6-di-tert-butylphenol]
CN   Biphenabid
CN   Bisbid
CN   Bisphenabid
CN   DH 581
CN   Lipomal
CN   Lorelco
CN   Lurselle
CN   NSC 652160
CN   NSC 86225
CN   Panavir
CN   Phenbutol
CN   Probucol
CN   Sinlestal
FS   3D CONCORD
MF   C31 H48 O2 S2
CI   COM
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS,
       BIOTECHNO, CA, CABA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN,
       CSCHEM, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSDRUGNEWS,
       IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROMT, PROUSDDR, PS,
       RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
         (*File contains numerically searchable property data)
     Other Sources:   EINECS**, WHO
         (**Enter CHEMLIST File for up-to-date regulatory information)
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

          1172 REFERENCES IN FILE CA (1907 TO DATE)
            27 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
          1173 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
```

FULL ESTIMATED COST 7.10 7.31

FILE 'CAPLUS' ENTERED AT 16:43:42 ON 10 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 May 2006 VOL 144 ISS 20
FILE LAST UPDATED: 9 May 2006 (20060509/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 23288-49-5 and ester
REGISTRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L3 1173 L2

577257 ESTER
L4 154 L3 AND ESTER

=> s (nah or sodium hydride) and l4
17520 NAH
1034404 SODIUM
100503 HYDRIDE
5474 SODIUM HYDRIDE
(SODIUM(W)HYDRIDE)
L5 2 (NAH OR SODIUM HYDRIDE) AND L4

=> d 1-2 ibib abs hitstr

L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:454275 CAPLUS
DOCUMENT NUMBER: 139:36349
TITLE: Preparation of arylalkyl-urea/carbamates for treatment of inflammation, diabetes and related disorders
INVENTOR(S): Neogi, Partha; Dey, Debendranath; Li, Ta-Kai; Fuller, Joseph; Chen, Liang
PATENT ASSIGNEE(S): Calyx Therapeutics Inc., USA
SOURCE: PCT Int. Appl., 107 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003048108	A2	20030612	WO 2002-US38150		20021127
WO 2003048108	A3	20031016			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2468302	AA	20030612	CA 2002-2468302		20021127
AU 2002357032	A1	20030617	AU 2002-357032		20021127
EP 1448515	A2	20040825	EP 2002-804467		20021127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
CN 1615295	A	20050511	CN 2002-827100		20021127
US 2004097593	A1	20040520	US 2003-430677		20030507
PRIORITY APPLN. INFO.:			US 2001-334818P	P	20011129
			WO 2002-US38150	W	20021127

OTHER SOURCE(S): MARPAT 139:36349
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1-7 = H, alkyl, chloroalkyl, alkenyl, etc.; R8-9 = H, alkyl, alkenyl, heteroaryl, etc.; R10-12 = H, alkyl, alkenyl, aryl, heteroaryl, etc.; X = O, N, SO-2,etc.; Y = O, S, NH; Z = alkoxy, alkyl, chloroalkyl, etc.] and related analogs are prepared For instance, 3-[3,5-dimethoxyphenyl]-2-[4-hydroxyphenyl]acrylic acid (preparation given) is reacted with 4-fluorobenzaldehyde (DMSO, KOBu-t, 100°, 5 h), the resulting aldehyde is reacted with triethylphosphonoacetate (THF, **NaH**), the disubstituted olefin is then selectively reduced (EtOH-dioxane, H2-Raney Ni), the **ester** reacted with urea (EtOH, NaOEt) and finally esterified to give II. A selected example compound has IC50 < 1 μM for PDE4 and IC50 = 13.6 μM for PDE3 and inhibits LPS-induced phosphorylation of p44/42 MAP kinase at 30 μM. I are effective inhibiting the cytokine-mediated inflammatory response in cultured cells, in ameliorating bone destruction, in an animal model of arthritis and in lowering blood glucose levels in animal models of Type II diabetes mellitus. I are also useful for a variety of treatments including the treatment of diabetes mellitus, insulin resistance, inflammation, inflammatory diseases, immunol. diseases and cancer.

IT **23288-49-5**, Probucol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination pharmaceutical; preparation of arylalkyl-urea/carbamates for treatment of inflammation, diabetes and related disorders)

RN 23288-49-5 CAPLUS

CN Phenol, 4,4'-[(1-methylethylidene)bis(thio)]bis[2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:319885 CAPLUS
DOCUMENT NUMBER: 138:338158
TITLE: Preparation of benzoxazine- and benzothiazine-containing β-aryl-α-oxypropionic acid derivatives and pharmaceutical compositions containing them as hPPARα and hPPARγ agonists with therapeutic uses
INVENTOR(S): Bhuniya, Debnath; Das, Saibal Kumar; Madhavan, Gurram Ranga; Iqbal, Javed; Chakrabarti, Ranjan
PATENT ASSIGNEE(S): Reddy's Laboratories Ltd., India
SOURCE: PCT Int. Appl., 161 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003033481	A1	20030424	WO 2002-IB4275		20021015
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2463686	AA	20030424	CA 2002-2463686		20021015
EP 1436268	A1	20040714	EP 2002-775090		20021015
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
BR 2002013350	A	20041013	BR 2002-13350		20021015
CN 1589258	A	20050302	CN 2002-822723		20021015
CN 1596249	A	20050316	CN 2002-823822		20021015
US 2005113368	A1	20050526	US 2003-492454		20021015
JP 2005527480	T2	20050915	JP 2003-536221		20021015
ZA 2004002858	A	20050112	ZA 2004-2858		20040415
ZA 2004002910	A	20050113	ZA 2004-2910		20040416
NO 2004001998	A	20040702	NO 2004-1998		20040514
PRIORITY APPLN. INFO.:			IN 2001-MA848	A	20011016
			WO 2002-IB4275	W	20021015

OTHER SOURCE(S): MARPAT 138:338158
GI



I



II

AB The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic benzoxazine and benzothiazine derivs. (shown as I; variables defined below; e.g. Et 3-[4-[[3-(3,4-dihydro-2H-benzo[b][1,4]oxazin-4-yl)propyl]amino]phenyl]-2-ethoxypropanoate (II)), their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compns. containing them, to a process for preparing such compds. and intermediates involved in preparation of I. Several methods of preparation are claimed and 22 example prepns. of intermediates and 72 of I are included. For example, II was prepared in 30% yield from Et 2-ethoxy-3-(4-aminophenyl)propanoate, 3-(3,4-dihydro-2H-benzo[b][1,4]oxazin-4-yl)propyl bromide and K2CO3 in DMF. The reactant Et 2-ethoxy-3-(4-aminophenyl)propanoate was prepared in 60 % yield from the Wittig salt, from tri-Et 2-ethoxyphosphonoacetate and **NaH**, and 4-nitrobenzaldehyde followed by hydrogenation. The other reactant, 3-(3,4-dihydro-2H-benzo[b][1,4]oxazin-4-yl)propyl bromide, was obtained in 47% yield from 3,4-dihydro-2H-benzo[b][1,4]oxazine, 1,3-dibromopropane and Na2CO3 in DMF. The efficacy of I was demonstrated via the following tests: in vitro hPPARα and hPPARγ activities and in vivo reduction in blood glucose and triglyceride, total cholesterol, LDL and VLDL levels and increase in HDL level. For I: R1, R2 and R3, R4 when attached to C = H, halogen, hydroxy, nitro, cyano, formyl or (un)substituted alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyalkyl, amino, acylamino, monoalkylamino, dialkylamino, arylamino, aralkylamino, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, carboxylic acid or its derivs., or sulfonic acid or its derivs.; one or both of R3 and R4 = oxo or thioxo group when they are attached to C. R3 and R4 when attached to N = H, hydroxy, formyl or (un)substituted alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, heterocyclyl, heteroaryl, heteroaralkyl, acyl, acyloxy, hydroxyalkyl, amino, acylamino, monoalkylamino, dialkylamino, arylamino, aralkylamino, aminoalkyl, aryloxy, aralkoxy, heteroaryloxy, heteroaralkoxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl groups, carboxylic acid derivs., or sulfonic acid derivs. X = O or S; Z = (CR10R11)n-W-(CR10R11)m-Ar-CHR5CR6(OR7)C(O)YR8; W = NR12, -C(O)(CR10R11)oNR12, -O-aryl-(CR10R11)o-NR12, where R12 = H or (un)substituted alkyl, aryl or

aralkyl; o = 0-6; R10 and R11 = H or (un)substituted alkyl, alkoxy, aryl or aralkyl; Ar = (un)substituted divalent single or fused aromatic or heterocyclic divalent phenylene, naphthylene, pyrrolyl, pyridyl, quinolinyl, benzofuryl, dihydrobenzofuryl, benzopyranyl, dihydrobenzopyranyl, indolyl, indolinyl, azaindolyl, azaindolinyl, pyrazolyl, benzothiazolyl or benzoxazolyl; R5 = H, hydroxy, alkoxy, halogen, alkyl, (un)substituted aralkyl or forms a bond together with the adjacent group R6. R6 = H, hydroxy, alkoxy, halogen, alkyl, acyl, (un)substituted aralkyl or R6 forms a bond together with R5; R7 = H or (un)substituted alkyl, cycloalkyl, aryl, aralkyl, alkoxyalkyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl, heteroaralkyl; R8 = H or (un)substituted alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl or heteroaralkyl; Y = O, S or NR9, where R9 = H or (un)substituted alkyl, aryl, hydroxyalkyl, aralkyl heterocyclyl, heteroaryl, or heteroaralkyl or NR9 = chiral amine, chiral amine alcs. derived from chiral amino acid; or R8 and R9 together form a (un)substituted 5 or 6 membered cyclic structure containing C atoms, which optionally contain ≥1 heteroatoms = O, S or N; m and n = 0-6.

IT **23288-49-5**, Probucol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combined with benzoxazine- and benzothiazine-containing β-aryl-α-oxypropionic acid derivative as hPPARα and hPPARγ agonists with therapeutic uses)

RN 23288-49-5 CAPLUS

CN Phenol, 4,4'-[(1-methylethylidene)bis(thio)]bis[2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> s  phenoxide and l4
          4772 PHENOXIDE
L6           0 PHENOXIDE AND L4

=> s  (acid anhydride or acid chloride) and l4
       4143979 ACID
        203654 ANHYDRIDE
         18172 ACID ANHYDRIDE
                 (ACID(W)ANHYDRIDE)
       4143979 ACID
       1074461 CHLORIDE
         26171 ACID CHLORIDE
                 (ACID(W)CHLORIDE)
L7           7 (ACID ANHYDRIDE OR ACID CHLORIDE) AND L4

=> d 1-7 ibib abs hitstr

L7   ANSWER 1 OF 7  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        2006:292785  CAPLUS
DOCUMENT NUMBER:         144:338238
```

TITLE: Drug-coated coronary stent system
INVENTOR(S): Orlowski, Michael
PATENT ASSIGNEE(S): Germany
SOURCE: Ger. Offen., 7 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 102004046244	A1	20060330	DE 2004-102004046244	20040922

PRIORITY APPLN. INFO.: DE 2004-102004046244 20040922

AB The invention concerns an expandable balloon with attached stent that is coated with an antiproliferative, antiinflammatory and/or antimycotic drug for the prevention of restenosis, infections and other complications after stent implantation. The balloons are prepared from a polymer. Typically a catheter with balloon is connected with the non-expanded stent and the two parts are coated with drugs simultaneously; a biostable or biodegradable layer can be added.

IT **23288-49-5**, Probucol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug-coated coronary stent system)

RN 23288-49-5 CAPLUS

CN Phenol, 4,4'-[(1-methylethylidene)bis(thio)]bis[2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:292462 CAPLUS
DOCUMENT NUMBER: 144:338236
TITLE: Method and device for coating medical goods using ultrasound spraying
INVENTOR(S): Sellin, Lothar; Han, Bock-Sun
PATENT ASSIGNEE(S): Germany
SOURCE: Ger. Offen., 13 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 102004038396	A1	20060330	DE 2004-102004038396	20040806

PRIORITY APPLN. INFO.: DE 2004-102004038396 20040806

AB The invention concerns a method and apparatus for coating medical goods by (a) placing the medical good in a vacuum chamber; (b) preparing a solution of the coating substance and placing it into a container in the chamber; (c)

applying vacuum; (d) nebulizing the solution using ultrasound and directing it onto the medical good for coating; and (e) airing the chamber and removing the coated medical good. Cpating materials are polymers and drugs; they are dissolved in organic solvents. Catheters, prosthetic materials, especially stents, endoscopes, tubes, implants, fibers, hollow fibers, syringes, surgical tools, sutures, dressings, microtiter plates, chromatog. stationary phases, chips, membranes, pacemakers, and valves can be coated.

IT **23288-49-5**, Probucol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method and device for coating medical goods using ultrasound spraying)

RN 23288-49-5 CAPLUS

CN Phenol, 4,4'-[(1-methylethylidene)bis(thio)]bis[2,6-bis(1,1-dimethylethyl)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:984057 CAPLUS
DOCUMENT NUMBER: 143:292623
TITLE: Biocompatible coating, method, and use of medical surfaces
INVENTOR(S): Hoffmann, Erika
PATENT ASSIGNEE(S): Hemoteq G.m.b.H., Germany
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082434	A2	20050909	WO 2005-DE327	20050227
WO 2005082434	A3	20051013		
WO 2005082434	B1	20051215		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: DE 2004-102004009850A 20040228
US 2004-551761P P 20040311

AB The invention relates to medical products having a surface that is at least partially covered by a polymer layer. Said polymer layer is

preferably formed by autopolymn. Substances containing at least one multiple bond, especially unsatd. fatty acids comprising an alkyl chain consisting of preferably between 7 and 50 carbon atoms are polymerized Other substances which do not participate in the polymerization can be added to the substances participating in the polymerization reaction. Said substances are preferably saturated fatty acids and fatty acid derivs. The invention also relates to methods for producing such medical products, and to the use of the same. Thus a non-expanding stent prepared from LVM 316 stainless steel was spray-coated with a mixture of linseed oil and paclitaxel at a ratio of 80:20 in chloroform at a ration of 1:1. Thereafter chloroform was evaporated and stored at 80°C.

IT **23288-49-5**, Probucol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biocompatible coating, method, and use of medical surfaces)

RN 23288-49-5 CAPLUS

CN Phenol, 4,4'-[(1-methylethylidene)bis(thio)]bis[2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:324038 CAPLUS

DOCUMENT NUMBER: 142:397825

TITLE: Biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers

INVENTOR(S): Horres, Roland; Hoffmann, Michael; Faust, Volker; Hoffmann, Erika; Di Biase, Donato

PATENT ASSIGNEE(S): Hemoteq G.m.b.H., Germany

SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005032611	A2	20050414	WO 2004-DE2184		20040929
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
DE 102004020856	A1	20050414	DE 2004-102004020856		20040428
US 2005129731	A1	20050616	US 2004-979977		20041103
PRIORITY APPLN. INFO.:			DE 2003-10345132	A	20030929
			US 2003-516295P	P	20031103

DE 2004-102004020856A 20040428
US 2004-571582P P 20040517

AB The invention relates to medical products comprising at least one biocompatible biostable polysulfone coating. Said polysulfone coating makes it possible, via the admixt. of an adequate quantity of at least one hydrophilic polymer, to control the elution kinetics of the at least one antiproliferative, anti-inflammatory, antiphlogistic, and/or antithrombogenic agent that is introduced and/or applied while allowing different agents or agent concns. to be spatially separated with the aid of the layer system of biostable polymers. Also disclosed are a method for producing said medical products and the use thereof particularly in the form of stents for preventing restenosis. Thus a 2 g base-coat solution for spray coating contained 17.6 mg polyethersulfone(Udel form Solvay) in chloroform. The 3 g chloroformic topcoat solution included 25.2 g polyethersulfone and 1,2 mg PVP.

IT **23288-49-5**, Probucol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

RN 23288-49-5 CAPLUS

CN Phenol, 4,4'-[(1-methylethylidene)bis(thio)]bis[2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:610066 CAPLUS
DOCUMENT NUMBER: 141:156929
TITLE: Process of preparing esters and ethers of probucol and derivatives thereof
INVENTOR(S): Weingarten, M. David; Sikorski, James A.
PATENT ASSIGNEE(S): Atherogenics, Inc., USA
SOURCE: PCT Int. Appl., 136 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004062622	A2	20040729	WO 2004-US805	20040113
WO 2004062622	A3	20041202		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
AU 2004204824	A1	20040729	AU 2004-204824	20040113
CA 2512980	AA	20040729	CA 2004-2512980	20040113
US 2004204485	A1	20041014	US 2004-757664	20040113
EP 1594824	A2	20051116	EP 2004-701812	20040113
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

BR 2004006738	A	20051220	BR 2004-6738		20040113
CN 1759084	A	20060412	CN 2004-80006265		20040113
PRIORITY APPLN. INFO.:			US 2003-439665P	P	20030113
			WO 2004-US805	W	20040113

OTHER SOURCE(S): MARPAT 141:156929
GI



I

AB Probucol or a probucol derivative can be efficiently converted to a monoester or monoether of probucol (I) [wherein R1-R4 = H, (un)substituted alkyl; R5, R6 = each (un)substituted alkyl, alkenyl, or aryl; or R5 and R6 can come together to form a carbocyclic ring; X, Y = H, optionally substituted (un)saturated acyl having from 1 to 18 carbon atoms each optionally containing a polar or charged functionality] by reacting the free hydroxyl-containing probucol or a derivative thereof (by which is meant a probucol compound with at least one substituent that is different from that on the parent probucol mol. but which maintains the two free hydroxyl groups), i.e., I (X = Y = H; R1-R6 = same as above), with a Grignard reagent or a lithium reagent that produces a magnesium bromide or lithium salt of probucol or the probucol derivative The probucol compound anion is then reacted with an **ester** or ether forming compound Thus, in a dry 25 mL 3-neck round bottom flask fitted with a reflux condenser, nitrogen inlet, thermocouple and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous toluene and then isopropylmagnesium chloride (0.51 mL, 2.0 M in THF) in 1 portion. The reaction was brought to room temperature and then succinic anhydride (0.25 g, 2.5 mmol) was added in 1 portion. After aging for 45 min, the reaction was slowly quenched with 1 N HCl and diluted with EtOAc. The biphasic reaction was then cooled to room temperature and the phases were separated to give an organic layer containing 60% probucol monosuccinate, 13% probucol disuccinate, and 27% probucol according to HPLC anal.

IT **23288-49-5**, Probucol
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of esters and ethers of probucol and its derivs. by treatment of probucol and its derivs. with Grignard reagent or organolithium reagent and then **ester** or ether forming compound)

RN 23288-49-5 CAPLUS
CN Phenol, 4,4'-[(1-methylethylidene)bis(thio)]bis[2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:913055 CAPLUS
DOCUMENT NUMBER: 139:399770
TITLE: Medical goods comprising heparin or chitosan-based hemocompatible coating
INVENTOR(S): Horres, Roland; Linssen, Marita Katharina; Hoffmann, Michael; Faust, Volker; Hoffmann, Erika; Di Biase, Donato
PATENT ASSIGNEE(S): Hemoteq G.m.b.H., Germany
SOURCE: PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003094990	A1	20031120	WO 2003-DE1253	20030415
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10221055	A1	20031127	DE 2002-10221055	20020510
DE 10261986	A1	20040318	DE 2002-10261986	20020510
AU 2003240391	A1	20031111	AU 2003-240391	20030415
CA 2484269	AA	20031120	CA 2003-2484269	20030415
CN 1543362	A	20041103	CN 2003-800770	20030415
EP 1501565	A1	20050202	EP 2003-729829	20030415
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003011446	A	20050315	BR 2003-11446	20030415
US 2005176678	A1	20050811	US 2003-513982	20030415
CN 1665554	A	20050907	CN 2003-815926	20030415
JP 2005534724	T2	20051117	JP 2004-503070	20030415
ZA 2004008791	A	20050527	ZA 2004-8791	20041028
ZA 2004008757	A	20050531	ZA 2004-8757	20041028

PRIORITY APPLN. INFO.:		
US 2002-378676P	P	20020509
DE 2002-10221055	A	20020510
WO 2003-DE1253	W	20030415

AB The invention relates to oligo- and polysaccharides containing the sugar structural element N-acylglucosamine or N-acylgalactosamine, in addition to the use thereof for producing hemocompatible surfaces and to methods for coating surfaces in a hemocompatible manner with said oligo- and polysaccharides, which constitute the common biosynthetic precursor substances of heparin, heparan sulfates and chitosan. The invention also relates to methods for producing the oligo- and/or polysaccharides, in addition to diverse application options involving hemocompatible surfaces. The invention specifically relates to the use of the oligo- and/or polysaccharides on stents involving at least one hemocompatible coating that has been applied according to the invention and that contains an anti-proliferative, anti-inflammatory and/or athrombogenic active ingredient, to methods for producing said stents and to the use of the latter for preventing restenosis. Thus desulfated and reacetylated heparin was prepared; the Ac-heparin product was used for coating coronary metal stents. The stents were implanted in swines; after four weeks the

animals were anesthetized and the artery segments removed for histomorphometric anal.

IT **23288-49-5**, Probucol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medical goods comprising a heparin-based hemocompatible coating)

RN 23288-49-5 CAPLUS

CN Phenol, 4,4'-[(1-methylethylidene)bis(thio)]bis[2,6-bis(1,1-dimethylethyl)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:863541 CAPLUS

DOCUMENT NUMBER: 135:371524

TITLE: Process for preparing water-soluble probucol acyl esters for use as food antioxidants

INVENTOR(S): Jass, Paul Alan

PATENT ASSIGNEE(S): Salsbury Chemicals, Inc., USA

SOURCE: U.S., 5 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6323359	B1	20011127	US 2000-562657	20000502
PRIORITY APPLN. INFO.:			US 2000-562657	20000502

OTHER SOURCE(S): CASREACT 135:371524; MARPAT 135:371524

GI



I



II

AB Water-soluble derivs. of probucol compds. [I; R1, R2 = alkyl, alkenyl, aryl; R3-R6 = C1-4 alkyl; X, Y = H, (un)saturated (un)substituted C1-8 acyl] (e.g., probucol mono- and disuccinate), useful as food antioxidants, are prepared by the reaction of a solution of a probucol compound (II) with an alkali metal hydroxide, alkali metal alkoxide (e.g., potassium tert-butoxide), alkylammonium alkoxide, alkylammonium hydroxide and mixts. forming an ammonium or an alkali metal salt of the probucol compound and reacting the salt with a carboxylic **acid anhydride** selected from succinic anhydride, glutaric anhydride, adipic anhydride, suberic anhydride, sebacic anhydride, azelaic anhydride, phthalic anhydride, and maleic anhydride.

IT **23288-49-5**, Probucol
RL: RCT (Reactant); RACT (Reactant or reagent)
(in a process for preparing water-soluble probucol acyl esters for use as food antioxidants)

RN 23288-49-5 CAPLUS

CN Phenol, 4,4'-[(1-methylethylidene)bis(thio)]bis[2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>